Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults with a baseline BMI >25 kg/m2. While the primary endpoint of SUSTAIN 7 was change in HbA1c, this post-hoc exploratory analysis examined the secondary endpoint of change in body weight by baseline BMI. The results will be presented 24 June, 2018 at the American Diabetes Association’s 78th Scientific Sessions (ADA) in Orlando, US.
Greater weight reductions were demonstrated across all BMI subgroups (<25, 25-<30, 30-<35, >35 kg/m2) with Ozempic® 0.5 mg vs dulaglutide 0.75 mg (range of weight reduction across all subgroups: 3.6–5.5 kg vs 0.9–3.4 kg) and with Ozempic® 1.0 mg vs dulaglutide 1.5 mg (range of weight reduction across all subgroups: 5.2–7.6 kg vs 2.0–3.8 kg), from a mean baseline of 95.2 kg. Adults with a higher baseline BMI (>25 kg/m2) taking Ozempic® generally achieved greater weight reductions than those with lower baseline BMI (<25 kg/m2).
In addition, more people achieved weight reductions of >5% and >10% with Ozempic® vs dulaglutide in all BMI subgroups.
“Globally, up to ninety percent of people with type 2 diabetes are overweight or have obesity.2 Therefore, it is important to consider how to manage weight in this population,” said Dr Adie Viljoen, SUSTAIN 7 chief investigator and consultant chemical pathologist, East and North Hertfordshire NHS Trust, UK. “Based on the SUSTAIN clinical trial programme, Ozempic® can help people living with type 2 diabetes manage their HbA1C and has the potential to help them lose some weight.”
Across BMI subgroups, fewer people reported gastrointestinal (GI) adverse events with the low dulaglutide dose (0.75 mg) compared with the other three treatment groups (Ozempic® 0.5 and 1.0 mg and dulaglutide 1.5 mg). The most common adverse events (>5%) for both Ozempic® dosages were GI adverse events.